Stock Analysis

What Percentage Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Do Insiders Own?

NasdaqCM:CRBP
Source: Shutterstock

The big shareholder groups in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes 'a business with enduring competitive advantages that is run by able and owner-oriented people'. So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

With a market capitalization of US$329m, Corbus Pharmaceuticals Holdings is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about CRBP.

See our latest analysis for Corbus Pharmaceuticals Holdings

NasdaqGM:CRBP Ownership Summary, September 4th 2019
NasdaqGM:CRBP Ownership Summary, September 4th 2019
Advertisement

What Does The Institutional Ownership Tell Us About Corbus Pharmaceuticals Holdings?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors own 43% of Corbus Pharmaceuticals Holdings. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Corbus Pharmaceuticals Holdings, (below). Of course, keep in mind that there are other factors to consider, too.

NasdaqGM:CRBP Income Statement, September 4th 2019
NasdaqGM:CRBP Income Statement, September 4th 2019

Hedge funds don't have many shares in Corbus Pharmaceuticals Holdings. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Corbus Pharmaceuticals Holdings

The definition of company insiders can be subjective, and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Shareholders would probably be interested to learn that insiders own shares in Corbus Pharmaceuticals Holdings, Inc.. As individuals, the insiders collectively own US$18m worth of the US$329m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, with a 44% stake in the company, will not easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With a stake of 7.7%, private equity firms could influence the CRBP board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.